Financial Performance and Margin Dynamics
Alembic Pharmaceuticals reported a consolidated revenue of INR 2,150 Cr for Q1 FY27, representing a 26% increase compared to the same period last year. Net profit for the quarter rose 12% YoY to INR 173 Cr. The reported EBITDA margin was 16%, reflecting better utilization of manufacturing networks and strong volume contributions.
However, margins were partially impacted by a planned 150 basis point dilution due to ongoing investments in the US branded specialty platform. The company recently transitioned to a new tax regime, resulting in an effective tax rate of approximately 22% for the quarter.
Segmental Performance and India Branded Business
- International Generics: Grew 37% YoY, with the US market specifically contributing a 49% increase primarily through volume and new launches
- API Segment: Recorded 33% growth despite market pricing pressures, driven by strong demand and capacity debottlenecking
- Animal Health: Delivered a robust 24% growth, now accounting for 22% of the India business revenue
- India Human Health: Grew 7%, with specialty therapies like Gynecology, Gastrology, and Ophthalmology continuing to perform well
- Chronic Portfolio: Management is focusing on building a high-quality prescription base, with specialty businesses making up nearly 60% of total domestic revenue
Strategic Outlook and Guidance Raise
At the beginning of the year, we had indicated that the US Generics could grow in the low to mid-teens... we now expect the US business to grow mid to high teens in the year.
Capital Allocation and Debt Management
The company reported a gross debt of approximately INR 1,600 Cr as of June 2026. This increase from March levels was attributed to higher working capital requirements and increased receivables following strong sales. Management intends to optimize working capital and reduce debt levels to approximately 1x EBITDA over the coming quarters.
Recent capital expenditures amounted to INR 400 Cr, aimed at enhancing manufacturing capabilities and debottlenecking facilities to support long-term growth. R&D expenditure for the quarter was INR 186 Cr, representing 9% of total revenue.
What to Watch
- Expiration of the 180-day marketing exclusivity for Bosutinib strengths in November 2026
- Execution of the remaining 15 planned product launches in the US market for FY27
- Progress of the US branded specialty business toward its goal of reaching breakeven by year-end
- Impact of management changes in the India human health division on domestic growth rates
- Trajectory of the high-teens margin guidance for the core business as operating leverage scales
